Literature DB >> 14986047

Probability of prostate cancer as a function of the percentage of free prostate-specific antigen in patients with a non-suspicious rectal examination and total prostate-specific antigen of 4-10 ng/ml.

L Martínez-Piñeiro1, J M García Mediero, P González Gancedo, A Tabernero, D Lozano, J J López-Tello, J M Alonso-Dorrego, C Núñez, M L Picazo, R Madero, J J De La Peña.   

Abstract

Our aim was to assess the usefulness of measuring the percentage of free prostate specific antigen (PSA) in serum in relation to reducing the number of prostate biopsies in men with benign prostate examinations and serum PSA levels between 4 and 10 ng/ml. The percentage of free PSA (Immulite) in serum was analyzed prospectively in 500 men, all of whom underwent ultrasound-guided sextant prostate biopsies. Cancer was detected in 21.4% (107/500) of the patients. Using a free PSA cutoff of < or = 23% as a criterion for performing prostate biopsy would have detected 94.4% of cancers, avoided 18.8% of benign biopsies and yielded a positive predictive value of 25.3%. The percentage of free PSA increased with prostate volume. Mean total PSA and mean free percent PSA values increased as patient age increased, influencing the calculation of cutoff values, sensitivity and specificity. PSA density had a sensitivity and specificity not significantly different than the percentage of free PSA. Measurement of the percentage of free serum PSA improves the specificity of prostate cancer detection in patients with elevated total serum PSA levels and benign prostate examinations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14986047     DOI: 10.1007/s00345-003-0393-5

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  19 in total

1.  Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.

Authors:  J Morote; C X Raventós; J A Lorente; M A Lopez-Pacios; G Encabo; I de Torres; J Andreu
Journal:  J Urol       Date:  1997-08       Impact factor: 7.450

2.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

Authors:  W J Catalona; A W Partin; K M Slawin; M K Brawer; R C Flanigan; A Patel; J P Richie; J B deKernion; P C Walsh; P T Scardino; P H Lange; E N Subong; R E Parson; G H Gasior; K G Loveland; P C Southwick
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

3.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.

Authors:  W J Catalona; D S Smith; D K Ornstein
Journal:  JAMA       Date:  1997-05-14       Impact factor: 56.272

Review 4.  Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer.

Authors:  D L Woodrum; M K Brawer; A W Partin; W J Catalona; P C Southwick
Journal:  J Urol       Date:  1998-01       Impact factor: 7.450

5.  Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging.

Authors:  W J Catalona; P C Southwick; K M Slawin; A W Partin; M K Brawer; R C Flanigan; A Patel; J P Richie; P C Walsh; P T Scardino; P H Lange; G H Gasior; K G Loveland; K R Bray
Journal:  Urology       Date:  2000-08-01       Impact factor: 2.649

6.  The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.

Authors:  C Stephan; M Lein; K Jung; D Schnorr; S A Loening
Journal:  Cancer       Date:  1997-01-01       Impact factor: 6.860

7.  The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density.

Authors:  C H Bangma; R Kranse; B G Blijenberg; F H Schröder
Journal:  Urology       Date:  1995-12       Impact factor: 2.649

8.  Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

Authors:  William J Catalona; Jerome P Richie; Frederick R Ahmann; M'Liss A Hudson; Peter T Scardino; Robert C Flanigan; Jean B DeKernion; Timothy L Ratliff; Louis R Kavoussi; Bruce L Dalkin; W Bedford Waters; Michael T MacFarlane; Paula C Southwick
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

9.  Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer.

Authors:  Y T Chen; A A Luderer; R P Thiel; G Carlson; C L Cuny; T F Soriano
Journal:  Urology       Date:  1996-04       Impact factor: 2.649

10.  Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.

Authors:  W J Catalona; D S Smith; R L Wolfert; T J Wang; H G Rittenhouse; T L Ratliff; R B Nadler
Journal:  JAMA       Date:  1995-10-18       Impact factor: 56.272

View more
  2 in total

1.  Body mass index in relation to prostate-specific antigen-related parameters.

Authors:  Dandan Lin; Ting Liu; Luling Chen; Zongtao Chen
Journal:  BMC Urol       Date:  2021-09-16       Impact factor: 2.264

2.  Evaluation and multi-institutional validation of a novel urine biomarker lncRNA546 to improve the diagnostic specificity of prostate cancer in PSA gray-zone.

Authors:  Fei Liu; Xiaolei Shi; Fangming Wang; Sujun Han; Dong Chen; Xu Gao; Linhui Wang; Qiang Wei; Nianzeng Xing; Shancheng Ren
Journal:  Front Oncol       Date:  2022-08-12       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.